Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

GIP and the gut-bone axis - physiological, pathophysiological and potential therapeutic implications

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Effect of pituitary adenylate cyclase-activating polypeptide-27 on cerebral hemodynamics in healthy volunteers: A 3T MRI study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Procholecystokinin expression and processing in cardiac myocytes

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Serum proatrial natriuretic peptide concentrations during oral glucose-induced acute hyperinsulinemia in lean and obese men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Gluco-metabolic effects of pharmacotherapy-induced modulation of bile acid physiology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Effect of the incretin hormones on the endocrine pancreas in end-stage renal disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. N-acyl taurines are endogenous lipid messengers that improve glucose homeostasis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The influence by gut-derived hormones on bone remodelling appears increasingly important as research on the enteroendocrine-osseous axis accelerates. Glucose-dependent insulinotropic polypeptide (GIP) is secreted from the gut and potentiates insulin secretion in a glucose-dependent manner. GIP has, like the two other gut-derived hormones, glucagon-like peptide 1 and glucagon-like peptide 2, been shown to affect bone remodelling as part of the enteroendocrine-osseous axis. Observational studies have shown that a mutation in the GIP receptor causing reduced receptor signalling leads to lower bone mineral density and increased fracture risk. Rodent as well as human studies have shown that GIP causes serum levels of the bone resorption marker carboxy-terminal type 1 collagen crosslinks to decline. GIP may also increase bone formation indicating a potential uncoupling of bone resorption and formation. Here, we review past and recent discoveries elucidating the enteroendocrine-osseous axis with a special focus on GIP.

OriginalsprogEngelsk
TidsskriftPeptides
ISSN0196-9781
DOI
StatusE-pub ahead of print - 9 nov. 2019

ID: 58360545